Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PJ002
- Development stage
- Unknown
- Lead developer
- Chongqing Paijin Biotechnology
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
PJ002 is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Chongqing Peg-Bio Biopharm (also known as Chongqing Paijin Biotechnology) for the treatment of type 2 diabetes mellitus and obesity. Administered as a once-daily subcutaneous injection, PJ002 is designed to enhance glucose-dependent insulin secretion and support weight reduction. The peptide is produced using the company's proprietary TE-Pep platform, which utilizes a unique tandem expression design to achieve high-quality, low-cost manufacturing. It is currently in Phase 2 clinical development.
02
Targets
Beyond the preview
Go deeper on PJ002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PJ002.